Related Experiment Videos
Olanzapine in the treatment of pervasive developmental disorders: a case series analysis
Chrissoula Stavrakaki1, Ruxandra Antochi, Patricia C Emery
1Department of Psychiatry, University of Ottawa, and Child and Family Psychiatric Unit, Children's Hospital of Eastern Ontario, Ottawa, Ont. csgm91@rogers.com
Abstract:
Controlling the symptoms that are characteristic of patients with pervasive developmental disorders is often challenging. We report on the safety and efficacy of olanzapine in the treatment of 7 patients with pervasive developmental disorders. The patients were all male and ranged in age from 8 to 52 years. They received olanzapine doses of 5-10 mg/d along with their various other drug regimens. Patients were monitored and evaluated for a mean duration of 17.7 (range 12-26) months while on olanzapine therapy. Very few side effects were observed during treatment. All patients showed clinically significant improvement on the Clinical Global Impressions scale, as well as an improved score as measured by the Global Assessment of Functioning scale. Our observations support the use of long-term olanzapine therapy for symptom control in patients with pervasive developmental disorders.
Related Concept Videos
Antipsychotic Drugs: Typical and Atypical Agents
Psychosis: Goals of Pharmacotherapy
Psychosis and Antipsychotic Drugs: Overview
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Personality Disorders: Paranoid and Schizoid
Paranoid Personality Disorder
Paranoid personality disorder is...
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...